ChiCTR2500098012 版本V1.0 版本创建时间2025/02/28 11:24:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500098012 

最近更新日期:

Date of Last Refreshed on:

2025-02-28 11:23:59 

注册时间:

Date of Registration:

2025-02-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胸膜感染的病原学及临床分析

Public title:

Etiological and clinical analysis of pleural infection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胸膜感染的病原学及临床分析

Scientific title:

Etiological and clinical analysis of pleural infection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周靓 

研究负责人:

王凯歌 

Applicant:

Liang Zhou 

Study leader:

Kaige Wang 

申请注册联系人电话:

Applicant telephone:

+86 159 2861 1364

研究负责人电话:

Study leader's telephone:

+86 28 8542 3331

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2022324020160@stu.scu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

532951643@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc

Study leader's address:

No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025年审(151)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Committee of West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-24 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 85423637

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

china

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

经费或物资来源:

其他

Source(s) of funding:

Other

Target disease:

pleural infection

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 明确胸膜感染患者的临床特征 2. 明确胸膜感染患者的病原学特征  

Objectives of Study:

1. Clarify the clinical characteristics of patients with pleural infection 2. Clarify the etiological characteristics of patients with pleural infection

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 临床诊断标准(符合以下任一项): ① 发热 ② 外周血白细胞计数升高 ③ 血清C反应蛋白升高 2. 实验室或影像学证据(符合以下任一项): ① 胸腔积液肉眼可见脓性 ② 胸腔积液细菌培养阳性 ③ 胸腔积液革兰氏染色见细菌 ④ 胸腔积液生化检查: pH≤7.2;若无法获取pH值,则需满足:LDH>1000 U/L且葡萄糖≤2.2 mmol/L ⑤ 增强CT显示:胸膜感染(表现为伴有肺实变且强化的胸腔积液)且已排除其他感染源

Inclusion criteria

1. Clinical diagnostic criteria (meeting any one of the following): (1) Fever (2) Elevated peripheral blood white blood cell count (3) Elevated serum C-reactive protein 2. Laboratory or imaging evidence (meeting any one of the following): (1) Visible purulent pleural effusion to the naked eye (2) Positive bacterial culture of pleural effusion (3) Bacteria seen on Gram staining of pleural effusion (4) Biochemical examination of pleural effusion: pH <= 7.2; if pH value cannot be obtained, then it must meet: LDH > 1000 U/L and glucose <= 2.2 mmol/L (5) Enhanced CT shows: pleural infection (manifested as pleural effusion with lung consolidation and enhancement) and other infection sources have been excluded

排除标准:

① 年龄<18岁 ② 感染侧曾行肺切除术 ③ 无法获取同时获取:胸腔积液常规检查、生化检查及病原学检测结果 ④ 缺少胸腔引流前的胸腔超声数据

Exclusion criteria:

(1) <18 years old (2) Pulmonary resection was performed on the infected side (3) Can not obtain at the same time: pleural effusion routine examination, biochemical examination and etiological detection results (4) Lack of thoracic ultrasound data before thoracic drainage

研究实施时间:

Study execute time:

From 2025-03-12 00:00:00 To 2026-01-24 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-12 00:00:00 To 2025-12-01 00:00:00  

干预措施:

Interventions:

组别:

胸膜感染

样本量:

2000

Group:

pleural infection

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川大学华西医院  

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川大学华西天府医院 

单位级别:

三甲 

Institution
hospital:

Sichuan University West China Tianfu Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省人民医院金牛院区 

单位级别:

三甲 

Institution
hospital:

Jinniu Courtyard, Sichuan Provincial People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China 

Province:

Hunan 

City:

Changsha 

单位(医院):

中南大学湘雅二医院 

单位级别:

三甲 

Institution
hospital:

The Second Xiangya Hospital, Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shanxi 

City:

Xian 

单位(医院):

西安交通大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Xi 'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省天府新区人民医院 

单位级别:

三甲 

Institution
hospital:

Sichuan Tianfu New District People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

3个月生存情况

指标类型:

主要指标

Outcome:

3 months survival

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时长

指标类型:

次要指标

Outcome:

Length of stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口学特征

指标类型:

主要指标

Outcome:

Demographic characteristics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声特征

指标类型:

主要指标

Outcome:

Ultrasonic characteristics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CT特征

指标类型:

主要指标

Outcome:

CT features

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸水检验结果

指标类型:

次要指标

Outcome:

Results of the pleural fluid test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病原检查结果

指标类型:

次要指标

Outcome:

Etiological result

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生化检验指标

指标类型:

主要指标

Outcome:

Biochemical test index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过邮箱532951643@qq.com 联系研究负责人,且采用临床试验公共管理平台ResMan向公众开放查询, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact by E-mail of study leader (532951643@qq.com),and the data will be published in the public management platform of clinical trials ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-02-28 11:23:59